For example, 5 μM ruxolitinib inhibits the Stat3 and Akt/mTOR/Yap pathways in TGF-β1-induced NRK-49F cells and thereby relieves renal interstitial fibrosis in UUO mice [68], and ruxolitinib cream was shown to improve skin inflammation and reduce pruritus by downregulating multiple components of the JAK-STAT signaling cascade in studies of fluorescein isothiocyanate (FITC)-induced dermatitis in mice and human skin explants [67]. Here, AKT1 is linked to Pruritus.